Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RB1 | P06400 | 7/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.56 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | CDC42 | P60953 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028219 | 0.85 | RB1 (0.57) | RB1SIRT1SIRT2BRD3MAPT | |
| SCHEMBL5752391 | 0.85 | MAPT (0.70) | RB1SIRT1SIRT2BRD3MAPT | |
| SCHEMBL13780953 | 0.84 | RB1 (0.58) | RB1SIRT1SIRT2BRD3MAPT | |
| SCHEMBL2320201 | 0.83 | RB1 (0.70) | RB1SIRT1SIRT2BRD3MAPT | |
| SCHEMBL4025335 | 0.82 | RB1 (0.60) | RB1SIRT1SIRT2BRD3MAPT | |
| SCHEMBL31120777 | 0.79 | RB1 (0.53) | RB1SIRT1SIRT2BRD3MAPT | |
| SCHEMBL13748402 | 0.79 | RB1 (0.68) | RB1SIRT1SIRT2BRD3CDC42 | |
| SCHEMBL28862190 | 0.77 | RB1 (0.67) | RB1SIRT1SIRT2BRD3MAPT | |
| SCHEMBL31120762 | 0.77 | RB1 (0.50) | RB1SIRT1SIRT2BRD3MAPT | |
| SCHEMBL31120761 | 0.77 | BRD3 (0.52) | RB1SIRT1SIRT2BRD3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | RB1 4460/4885SIRT1 418/4885SIRT2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.